Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer is a research paper published in Molecular & Cellular Proteomics (2022). On theSindex it has a DataRank of 0. It has been cited 14 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: P30CA016056
National Cancer Institute
Grant: R01CA198096
National Cancer Institute
Grant: R21CA168454
National Cancer Institute
Grant: RO3 CA205178
National Cancer Institute
Grant: GM131800
National Institutes of Health
Grant: 5P30CA016056-40
Roswell Park Cancer Institute Cancer Center Support Grant
National Institutes of Health
Grant: 5R01CA198096-05
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium
National Institutes of Health
Grant: 3UL1TR001412-08S3
Buffalo Clinical and Translational Research Center
National Institutes of Health
Grant: 1R03CA205178-01A1
Genes determining sensitivity to oxygen and nutrient deprivation
National Institutes of Health
Grant: 5R35GM131800-02
Mechanistic Pharmacokinetics and Pharmacodynamics
National Institutes of Health
Grant: 1R21CA168454-01
Pancreas cancer combination therapy based on stromal modulators and nano-carriers
FWCI
1.12
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals